Psoriatic Arthritis

You have full text access to this OnlineOpen article

Prevalence of malignancy in psoriatic arthritis

  1. Sherry Rohekar1,5,
  2. Brian D. M. Tom2,
  3. Agnes Hassa3,
  4. Cathy T. Schentag3,
  5. Vernon T. Farewell2,
  6. Dafna D. Gladman4,6,*

Article first published online: 28 DEC 2007

DOI: 10.1002/art.23185

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 58, Issue 1, pages 82–87, January 2008

Additional Information

How to Cite

Rohekar, S., Tom, B. D. M., Hassa, A., Schentag, C. T., Farewell, V. T. and Gladman, D. D. (2008), Prevalence of malignancy in psoriatic arthritis. Arthritis & Rheumatism, 58: 82–87. doi: 10.1002/art.23185

Author Information

  1. 1

    University of Toronto, Toronto, Ontario, Canada

  2. 2

    Institute of Public Health, Cambridge, UK

  3. 3

    Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada

  4. 4

    Toronto Western Research Institute, Toronto, Ontario, Canada

  5. 5

    Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada

  6. 6

    Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada

*Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, 1E-410B, 399 Bathurst Street, Toronto, Ontario M5T 2S8, Canada

Publication History

  1. Issue published online: 28 DEC 2007
  2. Article first published online: 28 DEC 2007
  3. Manuscript Accepted: 7 SEP 2007
  4. Manuscript Received: 18 MAY 2007

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (194K)

REFERENCES

  • 1
    Gladman DD. Psoriatic arthritis. In HarrisED, BuddRC, FiresteinGS, GenoveseMC, SergentJS, RuddyS, SledgeCB, editors. Kellye's textbook of rheumatology, 7th ed. Philadelphia: Saunders Elsevier; 2004. p. 1155–64.
  • 2
    Gladman DD, Shuckett R, Russell ML, Thorne JC, Schachter RK. Psoriatic arthritis (PsA): an analysis of 220 patients. Q J Med 1987; 62: 127–41.
  • 3
    Gladman DD, Stafford-Brady F, Chang CH, Lewandowski K, Russell ML. Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol 1990; 17: 809–12.
  • 4
    Torre Alonso JC, Rodriquez Perez A, Arribas Castrillo JM, Ballina Garcia J, Riestra Noriega JL, Lopez Larrea C. Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. Br J Rheumatol 1991; 30: 245–50.
  • 5
    McHugh NJ, Balachrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology (Oxford) 2003; 42: 778–83.
  • 6
    Queiro-Silva R, Torre-Alonso JC, Tinture-Eguren T, Lopez-Lagunas I. A polyarticular onset predicts erosive and deforming disease in psoriatic arthritis. Ann Rheum Dis 2003; 62: 68–70.
  • 7
    Jones SM, Armas JB, Cohen MG, Lovell CR, Evison G, McHugh NJ. Psoriatic arthritis: outcome of disease subsets and relationship of joint disease to nail and skin disease. Br J Rheumatol 1994; 33: 834–9.
  • 8
    Hakulinen T, Isomaki H, Knekt P. Rheumatoid arthritis and cancer studies based on linking nationwide registries in Finland. Am J Med 1985; 78: 29–32.
  • 9
    Mellemkjaer L, Linet MS, Gridley G, Frisch M, Moller H, Olsen JH. Rheumatoid arthritis and cancer risk. Eur J Cancer 1996; 32A: 1753–7.
  • 10
    Thomas E, Brewster DH, Black RJ, Macfarlane GJ. Risk of malignancy among patients with rheumatic conditions. Int J Cancer 2000; 88: 497–502.
    Direct Link:
  • 11
    Baecklund E, Askling J, Rosenquist R, Ekbom A, Klareskog, L. Rheumatoid arthritis and malignant lymphomas [review]. Curr Opin Rheumatol 2004; 16: 254–61.
  • 12
    Frentz G, Olsen JH. Malignant tumours and psoriasis: a follow-up study. Br J Dermatol 1999; 140: 237–42.
    Direct Link:
  • 13
    Hannuksela-Svahn A, Pukkala E, Laara E, Poikolainen K, Karvonen J. Psoriasis, its treatment, and cancer in a cohort of Finnish patients. J Invest Dermatol 2000; 114: 587–90.
  • 14
    Boffetta P, Gridley G, Lindelof B. Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden. J Invest Dermatol 2001; 117: 1531–7.
  • 15
    Olsen JH, Moller H, Frentz G. Malignant tumors in patients with psoriasis. J Am Acad Dermatol 1992; 27: 716–22.
  • 16
    Margolis D, Bilker W, Hennessy S, Vittorio C, Santanna J, Strom BL. The risk of malignancy associated with psoriasis. Arch Dermatol 2001; 137: 778–83.
  • 17
    Gelfand JM, Berlin J, Van Voorhees A, Margolis DJ. Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch Dermatol 2003; 139: 1425–9.
  • 18
    Asten P, Barrett J, Symmons D. Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. J Rheumatol 1999; 26: 1705–14.
  • 19
    Franklin JP, Symmons DP, Silman AJ. Risk of lymphoma in patients with RA treated with anti-TNFα agents [review]. Ann Rheum Dis 2005; 64: 657–8.
  • 20
    Keystone EC. Safety of biologic therapies: an update [review]. J Rheumatol Suppl 2005; 74: 8–12.
  • 21
    Geborek P, Bladstrom A, Turesson C, Gulfe A, Petersson IF, Saxne T, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005; 64: 699–703.
  • 22
    Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti–tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004; 50: 1740–51.
    Direct Link:
  • 23
    Stern RS, Laird N, Melski J, Parrish JA, Fitzpatrick TB, Bleich HL. Cutaneous squamous-cell carcinoma in patients treated with PUVA. N Engl J Med 1984; 310: 1156–61.
  • 24
    Shephard SE, Panizzon RG. Carcinogenic risk of bath PUVA in comparison to oral PUVA therapy. Dermatology 1999; 199: 106–12.
  • 25
    Chakravarty EF, Genovese MC. Associations between rheumatoid arthritis and malignancy [review]. Rheum Dis Clin North Am 2004; 30: 271–84.
  • 26
    Cibere J, Sibley J, Haga, M. Rheumatoid arthritis and the risk of malignancy. Arthritis Rheum 1997; 40: 1580–6.
    Direct Link:
  • 27
    Baecklund E, Sundstrom C, Ekbom A, Catrina AI, Biberfeld P, Feltelius N, et al. Lymphoma subtypes in patients with rheumatoid arthritis: increased proportion of diffuse large B cell lymphoma. Arthritis Rheum 2003; 48: 1543–50.
    Direct Link:
  • 28
    Baecklund E, Ekbom A, Sparen P, Feltelius N, Klareskog L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ 1998; 317: 180–1.
  • 29
    Feltelius N, Ekbom A, Blomqvist P. Cancer incidence among patients with ankylosing spondylitis in Sweden 1965–95: a population based cohort study. Ann Rheum Dis 2003; 62: 1185–8.
  • 30
    Askling J, Klareskog L, Blomqvist P, Fored M, Feltelius N. Risk for malignant lymphoma in ankylosing spondylitis: a nationwide Swedish case-control study. Ann Rheum Dis 2006; 65: 1184–7.
  • 31
    Chibata A, Zhao S, Makuch RW, Wentworth C, Veith J, Wallis W. Lymphoma risk in ankylosing spondylitis patients is greater that that observed in the general population. Ann Rheum Dis 2004; 63(Suppl 1): 98.
  • 32
    Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course and outcome. Ann Rheum Dis 2005; 64(Suppl II): 14–7.
  • 33
    Stern RS, Lange R. Cardiovascular disease, cancer, and cause of death in patients with psoriasis: 10 years prospective experience in a cohort of 1,380 patients [published erratum appears in J Invest Dermatol 1989;92:300]. J Invest Dermatol 1988; 91: 197–201.
  • 34
    Margolis D, Bilker W, Hennessy S, Vittorio C, Santanna J, Strom BL. The risk of malignancy associated with psoriasis. Arch Dermatol 2001; 137: 778–83.
  • 35
    Stern RS. Lymphoma risk in psoriasis: results of the PUVA follow-up study. Arch Dermatol 2006; 142: 1132–5.
  • 36
    Lindelof B, Eklund G, Liden S, Stern RS. The prevalence of malignant tumors in patients with psoriasis. J Am Acad Dermatol 1990; 22: 1056–60.
  • 37
    Paul CF, Ho VC, McGeown C, Christophers E, Schmidtmann B, Guillaume JC, et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 yr cohort study. J Invest Dermatol 2003; 120: 211–6.
View Full Article (HTML) Get PDF (194K)